Emapalumab in pediatric patients with high-grade cytokine release syndrome associated with CAR T-cell therapy
Emapalumab seems to serve as an effective salvage therapy for patients experiencing high-grade CRS with inadequate response to low-dose glucocorticoids and/or tocilizumab following CAR-T therapy. These data supported the use of emapalumab in high-grade CRS as well as provide rationale for future prospective studies.
Authors
- Juan Qian
- Yanjing Tang
- Kang An (ORCID: https://orcid.org/0000-0003-4937-4567)
- Wenhua Shi (ORCID: https://orcid.org/0000-0003-4988-2641)
- Benshang Li
- Jing Zhang
- Jing Yang
- Tianyi Wang
- Chengming Fei
- Rujun Jia
- Meng Su
Institutions
- Shanghai Children's Medical Center (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-03-04
- DOI
- https://doi.org/10.3389/fimmu.2026.1679175
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00